{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:24:05Z","timestamp":1790799845069,"version":"4.1.0"},"reference-count":168,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013850","name":"Helmut Horten Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.02105","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:41:08Z","timestamp":1599698468000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":286,"title":["Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Fabienne","family":"Maibach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Sadozai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Morteza","family":"Seyed Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrclinonc.2013.208","article-title":"Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.","volume":"11","author":"Drake","year":"2014","journal-title":"Nat Rev Clin Oncol."},{"key":"B2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/bs.ai.2015.12.006","article-title":"Adoptive T-cell therapy for cancer.","volume":"130","author":"Yang","year":"2016","journal-title":"Adv Immunol."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-oncology: emerging targets and combination therapies.","volume":"8","author":"Marshall","year":"2018","journal-title":"Front Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev-cancerbio-030518-055552","article-title":"Cancer immunotherapy: beyond checkpoint blockade.","volume":"3","author":"Dougan","year":"2018","journal-title":"Annu Rev Cancer Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy.","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade.","volume":"359","author":"Ribas","year":"2018","journal-title":"Science."},{"key":"B7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"Paradigm shift in cancer immunotherapy: from enhancement to normalization.","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.18.00114","article-title":"Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials.","volume":"3","author":"Pons-Tostivint","year":"2019","journal-title":"JCO Precis Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1158\/2326-6066.CIR-18-0277","article-title":"T cell\u2013inflamed versus non-T cell\u2013inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection.","volume":"6","author":"Trujillo","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment.","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0130-1","article-title":"Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance.","volume":"50","author":"Park","year":"2018","journal-title":"Exp Mol Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/bjc.2017.220","article-title":"HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer.","volume":"117","author":"Barnes","year":"2017","journal-title":"Br J Cancer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating Immunity\u2019s roles in cancer suppression and promotion.","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1172\/jci80004","article-title":"From mice to humans: developments in cancer immunoediting.","volume":"125","author":"Teng","year":"2015","journal-title":"J Clin Invest."},{"key":"B15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy.","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2018.01.013","article-title":"Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone?","volume":"343","author":"Badalamenti","year":"2018","journal-title":"Cell Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma.","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/CLEP.S99021","article-title":"Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe \u2013 a systematic review of the literature.","volume":"8","author":"Svedman","year":"2016","journal-title":"Clin Epidemiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11912-012-0257-5","article-title":"Tumor-infiltrating lymphocytes in melanoma.","volume":"14","author":"Lee","year":"2012","journal-title":"Curr Oncol Rep."},{"key":"B20","article-title":"Immune cell profiling in cancer: molecular approaches to cell-specific identification.","volume":"1","author":"Lyons","year":"2017","journal-title":"NPJ Precis Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1200\/JCO.2008.17.3567","article-title":"A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers.","volume":"26","author":"Camp","year":"2008","journal-title":"J Clin Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2326-6066.cir-15-0143","article-title":"Reflections on the histopathology of tumor-infiltrating lymphocytes in melanoma and the host immune response.","volume":"3","author":"Mihm","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pathol.2015.12.006","article-title":"Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.","volume":"48","author":"Lee","year":"2016","journal-title":"Pathology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(01)00620-9","article-title":"Melanoma-stroma interactions: structural and functional aspects.","volume":"3","author":"Ruiter","year":"2002","journal-title":"Lancet Oncol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4103\/jpi.jpi_69_18","article-title":"Twenty years of digital pathology: an overview of the road travelled, what is on the horizon, and the emergence of vendor-neutral archives.","volume":"9","author":"Pantanowitz","year":"2018","journal-title":"J Pathol Inform."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.36967","article-title":"Topography of cancer-associated immune cells in human solid tumors.","volume":"7","author":"Kather","year":"2018","journal-title":"eLlife."},{"key":"B27","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/pcmr.12757","article-title":"Comparison of five different scoring methods in the evaluation of inflammatory infiltration (tumor-infiltrating lymphocytes) in superficial spreading and nodular melanoma.","volume":"32","author":"N\u011bmejcov\u00e1","year":"2019","journal-title":"Pigment Cell Melanoma Res."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6010025","article-title":"The peripheral and intratumoral immune cell landscape in cancer patients: a proxy for tumor biology and a tool for outcome prediction.","volume":"6","author":"Schnell","year":"2018","journal-title":"Biomedicines."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1158\/0008-5472.CAN-11-1316","article-title":"Prognostic and predictive impact of intra- and peritumoral immune infiltrates.","volume":"71","author":"Fridman","year":"2011","journal-title":"Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/pcmr.12371","article-title":"Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma.","volume":"28","author":"Lad\u00e1nyi","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","article-title":"Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.","volume":"72","author":"Erdag","year":"2012","journal-title":"Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/modpathol.2015.110","article-title":"Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.","volume":"28","author":"Kakavand","year":"2015","journal-title":"Mod Pathol."},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1593806","article-title":"Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis.","volume":"8","author":"Fu","year":"2019","journal-title":"Oncoimmunology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.","volume":"30","author":"Azimi","year":"2012","journal-title":"J Clin Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/jnci\/81.24.1893","article-title":"Model predicting survival in stage I melanoma based on tumor progression.","volume":"81","author":"Clark","year":"1989","journal-title":"J Natl Cancer Inst."},{"key":"B36","doi-asserted-by":"crossref","first-page":"2308s","DOI":"10.1158\/1078-0432.CCR-05-2504","article-title":"Pathology of melanoma.","volume":"12","author":"Elder","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:73.0.CO;2-5","article-title":"Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.","volume":"77","author":"Clemente","year":"1996","journal-title":"Cancer."},{"key":"B38","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1309\/G6EK-Y6EH-0LGY-6D6P","article-title":"Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma: a study of interobserver agreement.","volume":"115","author":"Busam","year":"2001","journal-title":"Am J Clin Pathol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1200\/JCO.2006.08.9755","article-title":"Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.","volume":"25","author":"Taylor","year":"2007","journal-title":"J Clin Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer melanoma staging system.","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0000000000000161","article-title":"Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinom.","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment.","volume":"348","author":"Joyce","year":"2015","journal-title":"Science."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition.","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.trecan.2017.09.006","article-title":"Migrating into the tumor: a roadmap for T cells.","volume":"3","author":"van der Woude","year":"2017","journal-title":"Trends Cancer."},{"key":"B45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coi.2015.11.009","article-title":"Cancer immune contexture and immunotherapy.","volume":"39","author":"Becht","year":"2016","journal-title":"Curr Opin Immunol."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28944-3","article-title":"Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.","volume":"8","author":"Halse","year":"2018","journal-title":"Sci Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/bs.ai.2015.12.002","article-title":"Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers.","volume":"130","author":"Becht","year":"2016","journal-title":"Adv Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/bjc.2016.17","article-title":"Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment.","volume":"114","author":"Park","year":"2016","journal-title":"Br J Cancer."},{"key":"B49","doi-asserted-by":"publisher","first-page":"14759","DOI":"10.18632\/oncotarget.14736","article-title":"Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma.","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget."},{"key":"B50","doi-asserted-by":"publisher","first-page":"24990","DOI":"10.18632\/oncotarget.4572","article-title":"Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.","volume":"6","author":"Baine","year":"2015","journal-title":"Oncotarget."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/cncr.26511","article-title":"Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I\/II melanoma.","volume":"118","author":"Jensen","year":"2012","journal-title":"Cancer."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4103\/2153-3539.86830","article-title":"Standardization of whole slide image morphologic assessment with definition of a new application: digital slide dynamic morphometry.","volume":"2","author":"Puppa","year":"2011","journal-title":"J Pathol Inform."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1073\/pnas.0611618104","article-title":"CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.","volume":"104","author":"Sharma","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"key":"B54","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.celrep.2018.03.086","article-title":"Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images.","volume":"23","author":"Saltz","year":"2018","journal-title":"Cell Rep."},{"key":"B55","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00428-018-2485-z","article-title":"Precision immunoprofiling by image analysis and artificial intelligence.","volume":"474","author":"Koelzer","year":"2019","journal-title":"Virchows Arch."},{"key":"B56","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-18-1481","article-title":"Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer.","volume":"24","author":"Wouters","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/1523-1747.ep12292705","article-title":"T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas.","volume":"108","author":"Lowes","year":"1997","journal-title":"J Invest Dermatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cell.2018.03.042","article-title":"The cancer genome atlas: creating lasting value beyond its data.","volume":"173","author":"Hutter","year":"2018","journal-title":"Cell."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00262-018-2150-z","article-title":"Quantifying tumor-infiltrating immune cells from transcriptomics data.","volume":"67","author":"Finotello","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw144","article-title":"Genomic analysis of immune cell infiltrates across 11 tumor types.","volume":"108","author":"Iglesia","year":"2016","journal-title":"J Natl Cancer Inst."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression.","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00014","article-title":"Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy.","volume":"9","author":"Durgeau","year":"2018","journal-title":"Front Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","article-title":"How do cytotoxic lymphocytes kill cancer cells?","volume":"21","author":"Mart\u00ednez-Lostao","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks.","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat Rev Cancer."},{"key":"B65","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","article-title":"The role of Type 1 conventional dendritic cells in cancer immunity.","volume":"4","author":"B\u00f6ttcher","year":"2018","journal-title":"Trends Cancer."},{"key":"B66","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer.","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/cncr.21283","article-title":"The predictive value of CD8, CD4, CD68 and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase.","volume":"104","author":"Piras","year":"2005","journal-title":"Cancer."},{"key":"B68","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/ijc.23543","article-title":"Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.","volume":"123","author":"Van Houdt","year":"2008","journal-title":"Int J Cancer."},{"key":"B69","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jid.2015.12.042","article-title":"Immunophenotyping of stage III melanoma reveals parameters associated with patient prognosis.","volume":"136","author":"Jacquelot","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8 + T cells are abundant and phenotypically distinct in human tumour infiltrates.","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/jci80445","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients.","volume":"125","author":"Chauvin","year":"2015","journal-title":"J Clin Invest."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1299303","article-title":"Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.","volume":"6","author":"Jacquelot","year":"2017","journal-title":"Oncoimmunology."},{"key":"B73","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/2326-6066.cir-13-0216","article-title":"CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful.","volume":"2","author":"Kim","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T cell help in cancer immunology and immunotherapy.","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","article-title":"T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.","volume":"74","author":"Raphael","year":"2015","journal-title":"Cytokine."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2017.43","article-title":"Regulatory T-cell heterogeneity and the cancer immune response.","volume":"6","author":"Ward-Hartstonge","year":"2017","journal-title":"Clin Transl Immunol."},{"key":"B77","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaad.2011.04.031","article-title":"Guidelines of care for the management of primary cutaneous melanoma. American academy of dermatology.","volume":"65","author":"Bichakjian","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jtbi.2017.02.022","article-title":"Modelling and investigation of the CD4+ T cells \u2013 macrophages paradox in melanoma immunotherapies.","volume":"420","author":"Eftimie","year":"2017","journal-title":"J Theor Biol."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1026504","article-title":"Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma.","volume":"4","author":"Grotz","year":"2015","journal-title":"Oncoimmunology."},{"key":"B80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cjp2.31","article-title":"The infiltration, and prognostic importance, of Th1 lymphocytes vary in molecular subgroups of colorectal cancer.","volume":"2","author":"Ling","year":"2016","journal-title":"J Pathol Clin Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1159\/000456600","article-title":"Higher numbers of T-Bet + tumor-infiltrating lymphocytes associate with better survival in human epithelial ovarian cancer.","volume":"41","author":"Xu","year":"2017","journal-title":"Cell Physiol Biochem."},{"key":"B82","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature22360","article-title":"Stability and function of regulatory T cells expressing the transcription factor T-bet.","volume":"546","author":"Levine","year":"2017","journal-title":"Nature."},{"key":"B83","doi-asserted-by":"publisher","first-page":"415","DOI":"10.4049\/jimmunol.1701188","article-title":"Unlocking the complexities of tumor-associated regulatory T cells.","volume":"200","author":"Chao","year":"2018","journal-title":"J Immunol."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01578","article-title":"Tregs: where we are and what comes next?","volume":"8","author":"Zhao","year":"2017","journal-title":"Front Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00262-014-1581-4","article-title":"Foxp3 expression in T regulatory cells and other cell lineages.","volume":"63","author":"Devaud","year":"2014","journal-title":"Cancer Immunol Immunother."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00279","article-title":"Turning the tide against regulatory T cells.","volume":"8","author":"Han","year":"2019","journal-title":"Front Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression \u2014 implications for anticancer therapy.","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.it.2019.04.005","article-title":"Regulatory immune mechanisms beyond regulatory T cells.","volume":"40","author":"Christoffersson","year":"2019","journal-title":"Trends Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","article-title":"Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion.","volume":"20","author":"Sawant","year":"2019","journal-title":"Nat Immunol."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1744946","article-title":"Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.","volume":"9","author":"Shevchenko","year":"2020","journal-title":"Oncoimmunology."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies.","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep."},{"key":"B92","first-page":"1115","article-title":"Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.","volume":"18","author":"Miracco","year":"2007","journal-title":"Oncol Rep."},{"key":"B93","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12253-010-9254-x","article-title":"FOXP3 + cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma.","volume":"16","author":"Lad\u00e1nyi","year":"2010","journal-title":"Pathol Oncol Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1600-0625.2011.01260.x","article-title":"Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma.","volume":"20","author":"Knol","year":"2011","journal-title":"Exp Dermatol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-13-2702","article-title":"In situ tumor PD-L1 mRNA expression is associated with increased tils and better outcome in breast carcinomas.","volume":"20","author":"Schalper","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-16-0431","article-title":"The emerging role of B cells in tumor immunity.","volume":"76","author":"Tsou","year":"2016","journal-title":"Cancer Res."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050449","article-title":"The B-side of cancer immunity: the underrated tune.","volume":"8","author":"Largeot","year":"2019","journal-title":"Cells."},{"key":"B98","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.trecan.2016.10.010","article-title":"Lymphocytes and cancer: a love\u2013hate relationship.","volume":"2","author":"Yuen","year":"2016","journal-title":"Trends Cancer."},{"key":"B99","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/cmi.2017.35","article-title":"B cell regulation in cancer and anti-tumor immunity.","volume":"14","author":"Sarvaria","year":"2017","journal-title":"Cell Mol Immunol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-10-4316","article-title":"Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells.","volume":"71","author":"Olkhanud","year":"2011","journal-title":"Cancer Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3121\/cmr.2010.891","article-title":"PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms.","volume":"8","author":"Desouki","year":"2010","journal-title":"Clin Med Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s00262-011-1071-x","article-title":"Prognostic impact of B-cell density in cutaneous melanoma.","volume":"60","author":"Lad\u00e1nyi","year":"2011","journal-title":"Cancer Immunol Immunother."},{"key":"B103","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.humpath.2016.03.022","article-title":"Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.","volume":"54","author":"Garg","year":"2016","journal-title":"Hum Pathol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/his.12437","article-title":"A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma.","volume":"65","author":"Martinez-Rodriguez","year":"2014","journal-title":"Histopathology."},{"key":"B105","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.4049\/jimmunol.0903009","article-title":"B cells are required for optimal CD4 + and CD8 + T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.","volume":"184","author":"DiLillo","year":"2010","journal-title":"J Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/modpathol.2016.28","article-title":"Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.","volume":"29","author":"Bosisio","year":"2016","journal-title":"Mod Pathol."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01830","article-title":"Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?","volume":"8","author":"Colbeck","year":"2017","journal-title":"Front Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"432","DOI":"10.4049\/jimmunol.1701269","article-title":"Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity.","volume":"200","author":"Engelhard","year":"2018","journal-title":"J Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy.","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer."},{"key":"B110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00407","article-title":"Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention.","volume":"7","author":"Saut\u00e8s-Fridman","year":"2016","journal-title":"Front Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajpath.2011.03.007","article-title":"Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling.","volume":"179","author":"Coppola","year":"2011","journal-title":"Am J Pathol."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1054598","article-title":"Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients.","volume":"5","author":"Hennequin","year":"2016","journal-title":"Oncoimmunology."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00830","article-title":"Tertiary lymphoid structures: an anti-tumor school for adaptive immune cells and an antibody factory to fight cancer?","volume":"8","author":"Teillaud","year":"2017","journal-title":"Front Immunol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/ni.3290","article-title":"Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma.","volume":"16","author":"Finkin","year":"2015","journal-title":"Nat Immunol."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1116-1","article-title":"Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients.","volume":"15","author":"Figenschau","year":"2015","journal-title":"BMC Cancer."},{"key":"B116","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.immuni.2015.08.006","article-title":"Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses.","volume":"43","author":"Joshi","year":"2015","journal-title":"Immunity."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00262-007-0286-3","article-title":"Density of DC-LAMP + mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor.","volume":"56","author":"Lad\u00e1nyi","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"B118","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1158\/0008-5472.CAN-12-1377","article-title":"Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases.","volume":"72","author":"Cipponi","year":"2012","journal-title":"Cancer Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4161\/onci.20492","article-title":"High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes.","volume":"1","author":"Martinet","year":"2012","journal-title":"Oncoimmunology."},{"key":"B120","doi-asserted-by":"crossref","DOI":"10.1038\/srep00765","article-title":"12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?","volume":"2","author":"Messina","year":"2012","journal-title":"Sci Rep."},{"key":"B121","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00018-017-2686-7","article-title":"CD4 and CD8 T lymphocyte interplay in controlling tumor growth.","volume":"75","author":"Ostroumov","year":"2018","journal-title":"Cell Mol Life Sci."},{"key":"B122","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer.","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol."},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1872-9","article-title":"Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer.","volume":"17","author":"Liu","year":"2019","journal-title":"J Transl Med."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4832-5","article-title":"The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer.","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Cancer."},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38272-1","article-title":"Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.","volume":"9","author":"Kurozumi","year":"2019","journal-title":"Sci Rep."},{"key":"B126","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.trecan.2015.07.008","article-title":"Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance.","volume":"1","author":"Medler","year":"2015","journal-title":"Trends Cancer."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/cncr.31774","article-title":"Choice of first-line therapy in metastatic melanoma.","volume":"125","author":"Gibney","year":"2019","journal-title":"Cancer."},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy.","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"B131","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer.","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu Rev Immunol."},{"key":"B132","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review.","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.3748\/wjg.v24.i20.2137","article-title":"Immune therapies in pancreatic ductal adenocarcinoma: where are we now?","volume":"24","author":"Hilmi","year":"2018","journal-title":"World J Gastroenterol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers.","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer."},{"key":"B136","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrc.2016.54","article-title":"The role of myeloid cells in cancer therapies.","volume":"16","author":"Engblom","year":"2016","journal-title":"Nat Rev Cancer."},{"key":"B137","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?","volume":"39","author":"Fares","year":"2019","journal-title":"Am Soc Clin Oncol Educ B."},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01474","article-title":"Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-A review from the melanoma perspective and beyond.","volume":"9","author":"Buder-Bakhaya","year":"2018","journal-title":"Front Immunol."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-204","article-title":"A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.","volume":"9","author":"Hamid","year":"2011","journal-title":"J Transl Med."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00151","article-title":"The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy.","volume":"9","author":"Horny\u00e1k","year":"2018","journal-title":"Front Immunol."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2072-1","article-title":"Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy.","volume":"67","author":"Balatoni","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1158\/0008-5472.CAN-17-3607","article-title":"The balance players of the adaptive immune system.","volume":"78","author":"Andersen","year":"2018","journal-title":"Cancer Res."},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells.","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med."},{"key":"B144","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance.","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature."},{"key":"B145","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1172\/JCI87324","article-title":"Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.","volume":"126","author":"Daud","year":"2016","journal-title":"J Clin Invest."},{"key":"B146","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma.","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade.","volume":"170","author":"Wei","year":"2017","journal-title":"Cell."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.ccell.2018.05.009","article-title":"Non-conventional inhibitory CD4+Foxp3-PD-1hi T cells as a biomarker of immune checkpoint blockade activity.","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell."},{"key":"B149","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy.","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med."},{"key":"B150","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.4287","article-title":"Towards the introduction of the \u2018Immunoscore\u2019 in the classification of malignant tumours.","volume":"232","author":"Galon","year":"2014","journal-title":"J Pathol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet."},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1460-4","article-title":"Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.","volume":"16","author":"Takada","year":"2018","journal-title":"J Transl Med."},{"key":"B153","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.humpath.2017.09.012","article-title":"The CD4\/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.","volume":"69","author":"Wang","year":"2017","journal-title":"Hum Pathol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1158\/1078-0432.ccr-18-1851","article-title":"The immunoscore: colon cancer and beyond.","volume":"26","author":"Angell","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B155","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-017-1310-9","article-title":"World-wide immunoscore task force: meeting report from the \u2018Melanoma Bridge\u2019, Napoli, November 30th-December 3rd, 2016.","volume":"15","author":"Galon","year":"2017","journal-title":"J Transl Med."},{"key":"B156","doi-asserted-by":"publisher","first-page":"14456","DOI":"10.1073\/pnas.1617699113","article-title":"High-performance multiplexed fluorescence in situ hybridization in culture and tissue with matrix imprinting and clearing.","volume":"113","author":"Moffitt","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar7042","article-title":"Multiplexed protein maps link subcellular organization to cellular states.","volume":"361","author":"Gut","year":"2018","journal-title":"Science."},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020247","article-title":"State-of-the-art of profiling immune contexture in the era of multiplexed staining and digital analysis to study paraffin tumor tissues.","volume":"11","author":"Parra","year":"2019","journal-title":"Cancers."},{"key":"B159","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.iotech.2019.05.001","article-title":"A user\u2019s perspective on GeoMxTM digital spatial profiling.","volume":"1","author":"Van","year":"2019","journal-title":"Immuno Oncol Technol."},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030283","article-title":"Multiplexed immunohistochemistry for molecular and immune profiling in lung cancer\u2014just about ready for prime-time?","volume":"11","author":"Hofman","year":"2019","journal-title":"Cancers."},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.31657","article-title":"Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes.","volume":"7","author":"Lin","year":"2018","journal-title":"eLife."},{"key":"B162","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/cyto.a.23053","article-title":"Imaging mass cytometry.","volume":"91","author":"Chang","year":"2017","journal-title":"Cytometry Part A."},{"key":"B163","article-title":"Highly multiplexed imaging mass cytometry allows visualization of tumor and immune cell interactions of the tumor microenvironment in FFPE tissue sections.","volume":"130","author":"Singh","year":"2017","journal-title":"Blood."},{"key":"B164","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.cell.2018.07.010","article-title":"Deep profiling of mouse splenic architecture with CODEX multiplexed imaging.","volume":"174","author":"Goltsev","year":"2018","journal-title":"Cell."},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6074.cricimteatiaacr18-a074","article-title":"Abstract A074: spatially resolved deep antigen profiling of single cells in FFPE tissue samples through CODEXTM.","author":"Gallina","year":"2019","journal-title":"Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018."},{"key":"B166","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation.","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01977","article-title":"Turn back the TIMe: targeting tumor infiltrating myeloid cells to revert cancer progression.","volume":"9","author":"Awad","year":"2018","journal-title":"Front Immunol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00262-007-0353-9","article-title":"Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma.","volume":"57","author":"Hillen","year":"2008","journal-title":"Cancer Immunol Immunother."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02105\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:41:14Z","timestamp":1599698474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.02105\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":168,"alternative-id":["10.3389\/fimmu.2020.02105"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.02105","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"article-number":"2105"}}